ALLMedicine™ Unstable Angina Center

Jul 29th, 2021 - Many studies have shown that leukocyte cell-derived chemotaxin 2 (LECT2) is associated with metabolic disorders, which is a risk factor of arteriosclerosis. We assessed the level of LECT-2 in patients with coronary artery disease (CAD) and its sev...

Jul 24th, 2021 - Some trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular outcome trial o...

Jul 20th, 2021 - This study aimed to evaluate the concentration of plasma elabela (ELA) in patients with coronary heart disease (CHD) and its correlation with the disease classification.We enrolled 238 patients diagnosed by coronary angiography as CHD and 86 contr...

Jul 18th, 2021 - Non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA) are caused often by destabilization of non-flow limiting inflamed coronary artery plaques. 18F-fluorodeoxyglucose (FDG) uptake with positron emission tomography/computed tomo...

Jul 9th, 2021 - Non-ST-elevation acute coronary syndrome (NSTE-ACS) comprises a broad spectrum of disease ranging from unstable angina to myocardial infarction. International guidelines recommend a routine invasive strategy for managing patients with NSTE-ACS at ...

Oct 17th, 2012 - This focused update addresses the use of the newly approved oral antiplatelet agents, prasugrel and ticagrelor, for the management of patients with UA/NSTEMI.

Jul 25th, 2012 - Although current practice guidelines provide an evidence-based approach to the management of acute coronary syndromes, application of the evidence by individual physicians has been suboptimal. This gap between comprehensive guidelines and actual p...

May 7th, 2011 - 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

Mar 30th, 2011 - 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

Mar 26th, 2010 - Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance.|2010|Crowe E,Lovibond K,Gray H,Henderson R,Krause T,|therapy,therapeutic use,therapy,diagnosis,therapeutic use,diagnosis,

Apr 6th, 2020 - The BRICK study is a prospective, double-blind, sham-controlled, randomized clinical trial in patients with non-ST elevation myocardial infarction and unstable angina undergoing cardiac catheterization and percutaneous coronary intervention who ar...

Dec 30th, 2019 - Inclusion Subjects who are males or females ≥ 19 years of age Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcino...

Jul 30th, 2019 - Coronary artery disease is defined as a disease of the arteries that vascularize the heart, resulting in myocardial ischemia, i.e. insufficient blood supply to the heart muscle. Eventually, it may be responsible for acute coronary syndrome that in...

Jul 30th, 2019 - This is a prospective cohort monocentric study. The primary objective of this study is to research the vulnerability degree of ateromatous plaques before and after a myocardial infarction, based on multiomics data, invasive and non-invasive imagin...

Jul 19th, 2019 - ALLEPRE enrols a population of residents in Emilia Romagna with a diagnosis of ACS (unstable angina, non-ST segment elevation myocardial infarction, ST segment elevation myocardial infarction) who were admitted to the specialist cardiological depa...

Summary Company Announcement Date: February 02, 2021 FDA Publish Date: February 03, 2021 Product Type: Drugs Reason for Announcement: Recall Reason Description Packaging error resulting in incorrect dosage listed Company Name: Apotex Corp Brand Na...

Oct 27th, 2020 - Daily icosapent ethyl (Vascepa) safely and effectively reduces fatal and nonfatal ischemic events in patients with reduced kidney function, a prespecified analysis of the REDUCE-IT RENAL study shows. "Some cardiovascular drugs are not as effective...

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Apr 2nd, 2020 - The reduction in cardiovascular (CV) events seen in the REDUCE-IT trial with icosapent ethyl (Vascepa, Amarin), a high-strength formulation of purified eicosapentaenoic acid (EPA), were directly related to on-treatment serum levels of EPA, and not...